Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis
- PMID: 2218421
Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis
Abstract
192 patients, most of them ambulatory, with acute exacerbation of chronic bronchitis were treated with 10- to 14-day courses of oral ofloxacin receiving 400 mg once daily or doxycycline first 200 mg and then 100 mg once daily in this randomized observer-blinded multicentre study. 98 patients were included in the ofloxacin group and 94 in the doxycycline group. The clinical efficacy was 86/87 (98.8%) in the ofloxacin group and 87/91 (91.2%) in the doxycycline group. The bacteriological efficacy was 31/34 (91.2%) in the ofloxacin group and 19/24 (79.2%) in the doxycycline group. Some patients had more than one pathogen. There was no statistically significant difference in efficacy between the two treatment groups; both treatments were highly effective and well tolerated. The adverse events showed an expected pattern. Ofloxacin treatment was discontinued in three patients. In conclusion, both treatments were found to have similar safety and efficacy and were well tolerated when used for treatment of acute exacerbations of chronic bronchitis.
Similar articles
-
Ofloxacin in the treatment of lower respiratory tract infections: report of a prospective, comparative trial.Clin Ther. 1991 Jul-Aug;13(4):460-6. Clin Ther. 1991. PMID: 1933997 Clinical Trial.
-
Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa.Curr Med Res Opin. 2006 Sep;22(9):1725-36. doi: 10.1185/030079906X121057. Curr Med Res Opin. 2006. PMID: 16968576 Clinical Trial.
-
The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.Respir Med. 2000 Nov;94(11):1029-37. doi: 10.1053/rmed.2000.0927. Respir Med. 2000. PMID: 11127487 Clinical Trial.
-
Optimal treatment strategies for acute exacerbations of chronic bronchitis: high-risk patients.Chemotherapy. 2001;47 Suppl 4:47-52; discussion 53-4. doi: 10.1159/000049180. Chemotherapy. 2001. PMID: 11586005 Review.
-
Acute exacerbation of chronic bronchitis: expanding short-course therapy.Int J Antimicrob Agents. 2005 Dec;26 Suppl 3:S156-63. doi: 10.1016/s0924-8579(05)80322-x. Int J Antimicrob Agents. 2005. PMID: 16543077 Review.
Cited by
-
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.Drugs. 1991 Nov;42(5):825-76. doi: 10.2165/00003495-199142050-00008. Drugs. 1991. PMID: 1723377 Review.
-
Ofloxacin in lower respiratory tract infections.Infection. 1991;19 Suppl 7:S372-7. doi: 10.1007/BF01715830. Infection. 1991. PMID: 1804786
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical